Automatically produced note
Boehringer Ingelheim S.A. concentrates 98% of Empagliflozin purchases
The pharmaceutical company was awarded $ 5.7 billion in the category in 2026, out of a total of $ 5.8 billion. Four companies sold the product in the period.
What was measured
Boehringer Ingelheim S.A. was awarded $ 5.7 billion in the Empagliflozin (tablets) category during 2026. The total for the category in the same period was $ 5.8 billion. The company's share in this category reached 98.0%. Four companies sold this product in the period.
The measured block
| Measured | Value | Where it comes from |
|---|---|---|
| Adjudicado a BOEHRINGER INGELHEIM S A en el rubro, 2026 | $ 5,7 mil millones | releases.amount.primaryAmount por awards.items.classification.id |
| Total del rubro en el año | $ 5,8 mil millones | suma de todos los proveedores del mismo código; una compra con más de un adjudicatario suma a cada uno, lo que subestima la participación y nunca la exagera |
| Participación de la empresa | 98,0% | cociente entre las dos filas anteriores |
| Empresas que vendieron el rubro | 4 | proveedores distintos con adjudicación en el código |
| Código de catálogo | 74987 | awards.items.classification.id (catálogo SICE) |
Reproduce this measurement:npx tsx src/jobs/daily-investigation.ts --lane=concentracion-rubro --dry-run
Context
Catalog code 74987 corresponds to Empagliflozin (tablets). Boehringer Ingelheim S.A. is a pharmaceutical company.
The rule it puts in play
Concentrating a category is not in itself an infraction: it may reflect a market with only one capable supplier. Competition defense law does prohibit agreeing or coordinating offers between competitors, and that is a different conduct that this measurement does not observe.
What is missing to say more
The current measurement does not allow determining whether Boehringer Ingelheim S.A.'s high concentration in the Empagliflozin category is due to a legitimate dominant position or anticompetitive practices. Information on the number of authorized suppliers and market structure would be needed to assess if there are entry barriers or if the concentration could be the result of agreements between competitors.
Who should answer
The Commission for the Promotion and Defense of Competition must answer whether the observed concentration in the Empagliflozin category complies with current regulations.
Tell it where you can be protected
We publish what is in the open data. What isn't — the file, the message, what was said in the meeting — goes to Uruguay Leaks, the anonymous inbox run by la diaria, PODER and DATA Uruguay. The message is written for you: copy it, add what you know and paste it into their form.
Do not send it from your work computer or work email. Uruguay Leaks protects the submission, not the machine you send it from.
Uruguay Leaks is a project by la diaria, PODER and DATA Uruguay. We are not affiliated with them and receive no copy of what you send.